Tomokazu Kawaoka

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri et al. · The Lancet · 2025 · 151 citations · Full text

Hepatology, Transarterial Chemoembolisation, Medicine +8

Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis

Yuko Nagaoki, Hiroshi Aikata, Kana Daijyo et al. · Hepatology Research · 2017 · 145 citations

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease

Takashi Nakahara, Hideyuki Hyogo, Atsushi Ono et al. · Journal of Gastroenterology · 2017 · 112 citations

Hepatology, Pathology, Liver Disease +4